Impact of drug transporter studies on drug discovery and development

被引:361
作者
Mizuno, N
Niwa, T
Yotsumoto, Y
Sugiyama, Y
机构
[1] Univ Tokyo, Grad Sch Pharmaceut Sci, Bunkyo Ku, Tokyo 1130033, Japan
[2] Mitsubishi Pharma Corp, Pharmacokinet Lab, Chiba, Japan
关键词
D O I
10.1124/pr.55.3.1
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Drug transporters are expressed in many tissues such as the intestine, liver, kidney, and brain, and play key roles in drug absorption, distribution, and excretion. The information on the functional characteristics of drug transporters provides important information to allow improvements in drug delivery or drug design by targeting specific transporter proteins. In this article we summarize the significant role played by drug transporters in drug disposition, focusing particularly on their potential use during the drug discovery and development process. The use of transporter function offers the possibility of delivering a drug to the target organ, avoiding distribution to other organs (thereby reducing the chance of toxic side effects), controlling the elimination process, and/or improving oral bioavailability. It is useful to select a lead compound that may or may not interact with transporters, depending on whether such an interaction is desirable. The expression system of transporters is an efficient tool for screening the activity of individual transport processes. The changes in pharmacokinetics due to genetic polymorphisms and drug-drug interactions involving transporters can often have a direct and adverse effect on the therapeutic safety and efficacy of many important drugs. To obtain detailed information about these interindividual differences, the contribution made by transporters to drug absorption, distribution, and excretion needs to be taken into account throughout the drug discovery and development process.
引用
收藏
页码:425 / 461
页数:37
相关论文
共 395 条
[1]   Identification of a novel gene family encoding human liver-specific organic anion transporter LST-1 [J].
Abe, T ;
Kakyo, M ;
Tokui, T ;
Nakagomi, R ;
Nishio, T ;
Nakai, D ;
Nomura, H ;
Unno, M ;
Suzuki, M ;
Naitoh, T ;
Matsuno, S ;
Yawo, H .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1999, 274 (24) :17159-17163
[2]  
Abu-Zahra TN, 2000, DRUG METAB DISPOS, V28, P801
[3]   BRAIN VIRAL BURDEN IN HIV-INFECTION [J].
ACHIM, CL ;
WANG, R ;
MINERS, DK ;
WILEY, CA .
JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY, 1994, 53 (03) :284-294
[4]   Comparative studies on in vitro methods for evaluating in vivo function of MDR1 P-glycoprotein [J].
Adachi, Y ;
Suzuki, H ;
Sugiyama, Y .
PHARMACEUTICAL RESEARCH, 2001, 18 (12) :1660-1668
[5]   Characterization of bile acid transport mediated by multidrug resistance associated protein 2 and bile salt export pump [J].
Akita, H ;
Suzuki, H ;
Ito, K ;
Kinoshita, S ;
Sato, N ;
Takikawa, H ;
Sugiyama, Y .
BIOCHIMICA ET BIOPHYSICA ACTA-BIOMEMBRANES, 2001, 1511 (01) :7-16
[6]   Rhabdomyolysis due to combination therapy with cerivastatin and gemfibrozil [J].
Alexandridis, G ;
Pappas, GA ;
Elisaf, MS .
AMERICAN JOURNAL OF MEDICINE, 2000, 109 (03) :261-262
[7]   Active apical secretory efflux of the HIV protease inhibitors saquinavir and ritonavir in Caco-2 cell monolayers [J].
Alsenz, J ;
Steffen, H ;
Alex, R .
PHARMACEUTICAL RESEARCH, 1998, 15 (03) :423-428
[8]   MDR1 pharmacogenetics:: frequency of the C3435T mutation in exon 26 is significantly influenced by ethnicity [J].
Ameyaw, MM ;
Regateiro, F ;
Li, T ;
Liu, XH ;
Tariq, M ;
Mobarek, A ;
Thornton, N ;
Folayan, GO ;
Githang'a, J ;
Indalo, A ;
Ofori-Adjei, D ;
Price-Evans, DA ;
McLeod, HL .
PHARMACOGENETICS, 2001, 11 (03) :217-221
[9]  
Amsden GW, 2000, J CLIN PHARMACOL, V40, P1522
[10]   Human bile salt export pump promoter is transactivated by the farnesoid X receptor/bile acid receptor [J].
Ananthanarayanan, M ;
Balasubramanian, N ;
Makishima, M ;
Mangelsdorf, DJ ;
Suchy, FJ .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2001, 276 (31) :28857-28865